IO Biotech Inc
IOBT0.664USD
+0.042+6.83%
收盤 12/19, 16:00（美東）報價延遲15分鐘
46.31M總市值
虧損本益比TTM
關於 IO Biotech Inc 公司
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
IO Biotech Inc簡介
公司代碼IOBT
公司名稱IO Biotech Inc
上市日期Nov 05, 2021
CEOZocca (Mai-Britt)
員工數量80
證券類型Ordinary Share
年結日Nov 05
公司地址Ole Maaloes Veh 3
城市COPENHAGEN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家Denmark
郵編2200
電話4570702980
網址https://www.iobiotech.com/
公司代碼IOBT
上市日期Nov 05, 2021
CEOZocca (Mai-Britt)
IO Biotech Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Mai-Britt Zocca, Ph.D.
Dr. Mai-Britt Zocca, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
76.47K
--
Mr. Devin Whittemore Smith
Mr. Devin Whittemore Smith
General Counsel, Company Secretary
General Counsel, Company Secretary
16.93K
+243.31%
Ms. Heidi Hunter
Ms. Heidi Hunter
Independent Director
Independent Director
15.00K
--
Mr. Brian Burkavage
Mr. Brian Burkavage
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
11.50K
+666.67%
Dr. Helen Louise Collins, M.D.
Dr. Helen Louise Collins, M.D.
Director
Director
--
--
Ms. Kathleen Sereda Glaub
Ms. Kathleen Sereda Glaub
Independent Director
Independent Director
--
--
Dr. Christian E. Elling, Ph.D.
Dr. Christian E. Elling, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Hirth, Ph.D.
Dr. Peter Hirth, Ph.D.
Chairman of the Board
Chairman of the Board
--
--
Mr. David V. Smith
Mr. David V. Smith
Independent Director
Independent Director
--
--
Dr. Faical Miyara, Ph.D.
Dr. Faical Miyara, Ph.D.
Chief Business Officer
Chief Business Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Mai-Britt Zocca, Ph.D.
Dr. Mai-Britt Zocca, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
76.47K
--
Mr. Devin Whittemore Smith
Mr. Devin Whittemore Smith
General Counsel, Company Secretary
General Counsel, Company Secretary
16.93K
+243.31%
Ms. Heidi Hunter
Ms. Heidi Hunter
Independent Director
Independent Director
15.00K
--
Mr. Brian Burkavage
Mr. Brian Burkavage
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
11.50K
+666.67%
Dr. Helen Louise Collins, M.D.
Dr. Helen Louise Collins, M.D.
Director
Director
--
--
Ms. Kathleen Sereda Glaub
Ms. Kathleen Sereda Glaub
Independent Director
Independent Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月17日 週一
更新時間: 11月17日 週一
持股股東
股東類型
持股股東
持股股東
佔比
Lundbeckfond Ventures
19.39%
Kurma Partners SA
9.48%
HBM Partners AG
5.48%
Chernett (Jorey)
4.83%
Novo Holdings A/S
3.49%
其他
57.32%
持股股東
持股股東
佔比
Lundbeckfond Ventures
19.39%
Kurma Partners SA
9.48%
HBM Partners AG
5.48%
Chernett (Jorey)
4.83%
Novo Holdings A/S
3.49%
其他
57.32%
股東類型
持股股東
佔比
Venture Capital
32.61%
Investment Advisor
6.58%
Hedge Fund
5.28%
Individual Investor
5.14%
Investment Advisor/Hedge Fund
2.37%
Research Firm
1.26%
其他
46.76%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
49
42.06M
63.84%
-13.38M
2025Q2
52
43.99M
66.77%
-12.21M
2025Q1
56
44.00M
66.79%
+640.94K
2024Q4
57
44.61M
67.71%
+1.88M
2024Q3
50
48.46M
73.56%
+5.16M
2024Q2
48
51.73M
78.53%
+7.90M
2024Q1
53
52.99M
80.43%
+6.73M
2023Q4
55
54.27M
82.38%
+8.45M
2023Q3
56
56.33M
89.04%
+20.70M
2023Q2
46
22.57M
78.34%
-5.75M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Lundbeckfond Ventures
13.95M
21.18%
--
--
Apr 11, 2025
Kurma Partners SA
6.82M
10.35%
--
--
Apr 11, 2025
HBM Partners AG
3.94M
5.99%
--
--
Apr 11, 2025
Novo Holdings A/S
2.51M
3.81%
-842.00K
-25.10%
Aug 11, 2025
Marshall Wace LLP
2.11M
3.2%
--
--
Jun 30, 2025
BofA Global Research (US)
1.62M
2.45%
-36.44K
-2.21%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
653.68K
0.99%
-135.78K
-17.20%
Jun 30, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
IO Biotech Inc的前五大股東是誰？
IO Biotech Inc的前五大股東如下：
Lundbeckfond Ventures持有股份：13.95M佔總股份比例：21.18%。
Kurma Partners SA持有股份：6.82M佔總股份比例：10.35%。
HBM Partners AG持有股份：3.94M佔總股份比例：5.99%。
Novo Holdings A/S持有股份：2.51M佔總股份比例：3.81%。
Marshall Wace LLP持有股份：2.11M佔總股份比例：3.20%。
Lundbeckfond Ventures持有股份：13.95M佔總股份比例：21.18%。
Kurma Partners SA持有股份：6.82M佔總股份比例：10.35%。
HBM Partners AG持有股份：3.94M佔總股份比例：5.99%。
Novo Holdings A/S持有股份：2.51M佔總股份比例：3.81%。
Marshall Wace LLP持有股份：2.11M佔總股份比例：3.20%。
IO Biotech Inc的前三大股東類型是什麼？
IO Biotech Inc 的前三大股東類型分別是：
Lundbeckfond Ventures
Kurma Partners SA
HBM Partners AG
Lundbeckfond Ventures
Kurma Partners SA
HBM Partners AG
有多少機構持有IO Biotech Inc(IOBT)的股份？
截至2025Q3，共有49家機構持有IO Biotech Inc的股份，合計持有的股份價值約為42.06M，占公司總股份的63.84% 。與2025Q2相比，機構持股有所增加，增幅為-2.94%。
哪個業務部門對IO Biotech Inc的收入貢獻最大？
在--，--業務部門對IO Biotech Inc的收入貢獻最大，創收--，占總收入的--% 。
